Molly Jenkins, Senior Director of Public Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), said that the 340B program is increasing Medicare costs by blocking rebates and worsening taxpayer burdens. Read More »
Ryan Long, Director and Senior Research Fellow at Paragon Health Institute, expressed concerns about the 340B Drug Pricing Program's impact on wealthier hospitals, costs, and safety-net providers. Read More »
Lori M. Reilly, Chief Operating Officer for the Pharmaceutical Research and Manufacturers of America (PhRMA), said that the 340B program is increasing taxpayer costs without demonstrated patient benefits and requires accountability and reform. Read More »
Sally Pipes, President and CEO of the Pacific Research Institute, expressed concerns regarding the 340B Drug Pricing Program, highlighting how government initiatives can be subject to corruption and misuse despite their intended purpose. Read More »
Reid Porter, Senior Director of State Public Affairs for the Pharmaceutical Research and Manufacturers of America (PhRMA), has expressed concerns over the misuse of the 340B Drug Pricing Program by large providers and their partners. Read More »
Dutch Rojas, founder of ReKlaim Health, said that the 340B program has deviated from its original mission to assist low-income patients and instead allows health systems to profit from drug pricing arbitrage. Read More »
A fifth COVID-19 vaccine is scheduled to enter a Phase III clinical trial in the coming weeks with 30,000 participants in the United States and Mexico. Read More »
The U.S. Food and Drug Administration (FDA) recently issued the first emergency use authorization (EUA) allowing the Pfizer-BioNTech COVID-19 vaccine to be distributed in the U.S., according to a release by the FDA. Read More »
Action from the U.S. Department of Health and Human Services (HHS) and Food and Drug Administration (FDA) has been challenged by the Pharmaceutical Research and Manufacturers of America (PhRMA), Partnership for Safe Medicines (PSM) and Council for Affordable Health Coverage (CAHC) for letting drugs from Canada into the country without the authorization of manufacturers' oversight. Read More »
The AZD1222 COVID-19 vaccine has shown positive early results, according to Astra Zeneca. Read More »
Federal agencies are coordinating efforts to prevent items that they have designated as a public health threat from entering the country. Read More »
The Food and Drug Administration (FDA) confirmed that all dispensers such as pharmacies will have to meet requirements that go into effect on Friday, Nov. 27, regardless of the American Pharmacists Association's (APhA) concerns that not all of the Drug Supply Chain Security Act requirements are undermined by COVID-19 pandemic responses. Read More »
While there are concerns about the unforeseen health impacts of a vaccine for COVID-19, a coalition of pharmaceutical companies has joined together to build confidence in the process and end result. Read More »
The U.S. Food and Drug Administration (FDA) recently released a warning for pregnant mothers regarding a family of medications that includes ibuprofen, naproxen, diclofenac, celecoxib and other nonsteroidal anti-inflammatory drugs (NSAIDs). Read More »
Several U.S. House Representatives fought to protect access for patients to affordable medicines and the Association for Accessible Medicines (AAM) applauds their effort, according to a news release. Read More »
The U.S. Food and Drug Administration (FDA) recently approved Pfizer’s drug XELJANZ (tofacitinib) for treatment of polyarticular course juvenile idiopathic arthritis (pcJIA). Read More »
Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl has issued a statement regarding the administration's choice of the most favored nation policy. Read More »
A recent letter to Congressional leaders from a coalition headed by the National Forum for Heart Disease and Stroke Prevention urges Congress to include payments for front-line pharmacists in the next COVID-19 relief package by designating them as providers under Medicare Part B. Read More »
The majority receiving COVID-19 experimental treatments are those patients hospitalized with the coronavirus, Cedars-Sinai Hospital Epidemiology Director Jonathan Grein said in a recent news release. Read More »
In a letter delivered to the majority and minority leaders of Congress, the American Pharmacists Association requested immediate action to address the growing need to expand COVID-19 testing and immunization services by providing all pharmacists with temporary provider status in Medicare Part B. Read More »
Alerts Sign-up
